EJPMR, 2026, 13(3), 74-80 **Review Article** **Impact Factor: 8.158**

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

ISSN (O): 2394-3211
ISSN (P): 3051-2573
Coden USA: EJPMAG

TRADITIONAL ANTI-ARTHRITIC MEDICINAL PLANTS: ETHNOPHARMACOLOGY, PHYTOCHEMISTRY AND MODERN VALIDATION

Astha Patel[1]*, Upasna Gadhiya[1], Dr. Kinjal Patel[2]

[1]Student, K. B. Raval College of Pharmacy, Shertha, Gandhinagar, Gujarat 382423, India.
[2]Professor, Department of Pharmacognosy, K.B. Raval College of Pharmacy, Shertha, Gandhinagar, Gujarat 382423, India.

***Corresponding Author: Astha Patel**

Student, K. B. Raval College of Pharmacy, Shertha, Gandhinagar, Gujarat 382423, India.

Email ID: https://doi.org/10.5281/zenodo.18796774

How to cite this Article: Astha Patel[1]*, Upasna Gadhiya[1], Dr. Kinjal Patel[2]*. (2026). Traditional Anti-Arthritic Medicinal Plants: Ethnopharmacology, Phytochemistry and Modern Validation. European Journal of Biomedical and Pharmaceutical Sciences, 13(3), 74–80.

Article Received on 02/02/2026 **Article Revised on 23/02/2026** **Article Published on 01/03/2026**

ABSTRACT

Arthritis, encompassing rheumatoid arthritis (RA) and osteoarthritis (OA), represents a major global health burden characterized by chronic inflammation, progressive cartilage degeneration, and functional disability. Although conventional therapies including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic disease-modifying anti-rheumatic drugs (DMARDs) provide symptomatic relief, their long-term use is often associated with significant adverse effects and economic limitations. Consequently, increasing attention has been directed toward traditional medicinal plants as potential multi-target therapeutic agents. Ethnopharmacological evidence from Ayurveda, Traditional Chinese Medicine, African traditional medicine, and other indigenous systems documents extensive use of plant-based remedies for inflammatory joint disorders. Phytochemical investigations reveal that bioactive constituents such as flavonoids (quercetin), polyphenols (curcumin, resveratrol), terpenoids (boswellic acids, andrographolide), alkaloids (berberine), and catechins (epigallocatechin gallate) exert anti-arthritic effects through modulation of key inflammatory pathways. These compounds suppress pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), inhibit NF-κB and JAK/STAT signaling, reduce oxidative stress, and prevent matrix metalloproteinase-mediated cartilage degradation. Preclinical and clinical studies support their efficacy in reducing disease activity, pain, and joint inflammation. However, challenges remain regarding standardization, safety profiling, pharmacokinetics, and large-scale randomized clinical validation. Integration of ethnopharmacology, phytochemistry, and modern molecular validation offers a promising framework for developing safer, evidence-based anti-arthritic therapeutics.

KEYWORDS: Traditional medicinal plants, Rheumatoid arthritis, Osteoarthritis, Anti-inflammatory agents, Natural products, Herbal therapeutics.

1. INTRODUCTION

Arthritis is a leading cause of disability worldwide, characterized by joint inflammation, cartilage degeneration, synovial hyperplasia, and chronic pain.[1] Osteoarthritis is primarily degenerative, whereas rheumatoid arthritis is an autoimmune disorder marked by persistent synovial inflammation and systemic manifestations.[2] The prevalence of arthritis increases with aging populations and lifestyle factors such as obesity and metabolic syndrome.[3]

Despite therapeutic advances, long-term use of NSAIDs and corticosteroids is associated with gastrointestinal ulceration, renal impairment, cardiovascular events, and endocrine disturbances.[4,5] Biologic DMARDs, though effective, remain expensive and increase susceptibility to infections.[6] These limitations have encouraged exploration of plant-derived alternatives that offer multi-target activity and improved safety profiles.[7]

Ethnopharmacology provides valuable insight into plant species traditionally used to treat inflammatory disorders. Approximately 25–30% of modern drugs originate from

natural products or their derivatives.[8] Numerous medicinal plants used in traditional systems demonstrate anti-inflammatory, antioxidant, and immunomodulatory properties relevant to arthritis management.[9]

2. GLOBAL BURDEN OF ARTHRITIS

The Global Burden of Disease Study estimates that osteoarthritis affects more than 528 million people globally.[10] Rheumatoid arthritis has a global prevalence of approximately 0.5–1% of the adult population.[11] Arthritis significantly reduces quality of life and contributes to disability-adjusted life years (DALYs).[12] The socioeconomic burden includes healthcare costs, productivity loss, and long-term disability.[13] In low- and middle-income countries, limited access to advanced biologics has reinforced reliance on traditional plant-based remedies.[14]

3. PATHOPHYSIOLOGY OF ARTHRITIS

3.1 Rheumatoid Arthritis

RA is characterized by: Autoantibody production (RF, anti-CCP)[15], Synovial hyperplasia and pannus formation[16], Pro-inflammatory cytokines: TNF-α, IL-1β, IL-6[17], Activation of NF-κB and JAK/STAT pathways[18], Matrix metalloproteinase (MMP) mediated cartilage degradation.[19]



Fig. 1: Pathophysiology of Rheumatoid arthritis.[15-19]

3.2 Osteoarthritis

OA involves: Mechanical stress and cartilage breakdown[20], Oxidative stress and chondrocyte apoptosis[21], Low-grade inflammation mediated by cytokines and prostaglandins[22], Plant-derived phytochemicals can modulate these molecular pathways, offering multi-target therapeutic potential.[23]



Fig. 2: Pathophysiology of osteoarthritis.[20-23]

4. ETHNOPHARMACOLOGICAL OVERVIEW

Ethnobotanical surveys report over 450 plant species used traditionally for arthritis management worldwide.[24] Major plant families include: Asteraceae, Fabaceae, Lamiaceae, Zingiberaceae, Amaranthaceae.[25]

Traditional medicinal systems documenting anti-arthritic plants include: Ayurveda (India), Traditional Chinese Medicine, African ethnomedicine, Native American medicine.[26-29]

Decoctions, poultices, oils, and powdered roots are commonly used preparations.[30]

5. MAJOR TRADITIONAL ANTI-ARTHRITIC MEDICINAL PLANTS

5.1 *Withania somnifera* (Ashwagandha)

Family: Solanaceae
Traditional system: Ayurveda
Traditionally used as a Rasayana herb for inflammatory disorders.[31]
Phytochemistry: Withanolides, Alkaloids, Steroidal lactones.[32]

Pharmacological evidence

Experimental studies demonstrate reduction in TNF-α and IL-1β levels and suppression of NF-κB signalling.[33] Clinical studies suggest improvement in joint pain and stiffness.[34]

5.2 *Zingiber officinale* (Ginger)

Family: Zingiberaceae
Contains gingerols, shogaols, and paradols.[35]
Ginger extracts inhibit COX and LOX pathways, reducing prostaglandin synthesis.[36] Randomized trials show reduction in osteoarthritis pain scores.[37]

5.3 *Curcuma longa* (Turmeric)

Family: Zingiberaceae

Curcumin is the principal bioactive compound.[38]

It inhibits NF-κB, TNF-α, IL-1β, and COX-2.[39]

Clinical trials demonstrate comparable efficacy to NSAIDs with fewer adverse effects.;[40]

5.4 *Boswellia serrata*

Contains boswellic acids that inhibit 5-lipoxygenase.[41]

Randomized controlled trials report improvement in knee OA symptoms.[42]

5.5 *Tinospora cordifolia*

Traditionally used in Ayurveda for inflammatory diseases.[43]
Demonstrates immunomodulatory and antioxidant activity.[44]

However, cases of herb-induced liver injury have been reported.[45]

Table 1: Selected Traditional Anti-arthritic Medicinal Plants.

Plant	Major Phytoconstituents	Mechanism of Actions	Evidence Level	References
Withania somnifera	Withanolides	TNF-α inhibition	Preclinical + Clinical	[31-34]
Curcuma longa	Curcumin	NF-κB inhibition	Clinical	[38-40]
Zingiber officinale	Gingeroles	COX inhibition	Clinical	[35-37]
Boswellia serrata	Boswellic acid	5-LOX inhibition	Clinical	[41-42]
Tinospora cordifolia	Diterpenoids	Immunomodulatory	Preclinical	[43-45]

6. PHYTOCHEMISTRY OF TRADITIONAL ANTI-ARTHRITIC MEDICINAL PLANTS

Plant-derived anti-arthritic activity is largely attributed to secondary metabolites including polyphenols, flavonoids, terpenoids, alkaloids, saponins, and glycosides. These phytoconstituents modulate inflammatory signaling cascades, oxidative stress, and immune dysregulation.[46]

6.1 Flavonoids

Flavonoids such as quercetin, kaempferol, luteolin, apigenin, and rutin are widely distributed in medicinal plants used for arthritis.[47] These compounds suppress NF-κB activation, inhibit COX-2 and iNOS expression, and reduce pro-inflammatory cytokines.[48] Quercetin specifically inhibits TNF-α-induced synovial inflammation and attenuates cartilage degradation in experimental arthritis.[49]

6.2 Polyphenols

Polyphenols exhibit potent antioxidant and anti-inflammatory effects by scavenging reactive oxygen species (ROS) and modulating MAPK and NF-κB pathways.[50] Resveratrol has demonstrated protective effects against cartilage destruction in collagen-induced arthritis models.[51]

6.3 Terpenoids and Triterpenes

Terpenoids, including boswellic acids, ursolic acid, and andrographolide, exert anti-arthritic effects through inhibition of 5-lipoxygenase and suppression of leukotriene synthesis.[52] Ursolic acid reduces

inflammatory cell infiltration and cytokine production in experimental models.[53]

6.4 Alkaloids

Alkaloids from medicinal plants demonstrate immunomodulatory properties. Berberine inhibits Th17 cell differentiation and reduces IL-17 production in rheumatoid arthritis models.[54]

6.5 Saponins and Glycosides

Saponins such as ginsenosides and steroidal glycosides regulate inflammatory mediators and prevent cartilage degeneration.[55]

7. ADDITIONAL PROMINENT ANTI-ARTHRITIC MEDICINAL PLANTS

7.1 *Andrographis paniculata*

Contains andrographolide, a diterpenoid lactone with potent anti-inflammatory activity.[56] Clinical trials indicate symptomatic improvement in rheumatoid arthritis patients.[57]

7.2 *Tripterygium wilfordii*

Used in Traditional Chinese Medicine for autoimmune disorders. Triptolide suppresses T-cell activation and inflammatory cytokines.[58] Controlled clinical trials demonstrate efficacy in RA comparable to methotrexate.[59] However, toxicity concerns limit widespread use.[60]

7.3 *Camellia sinensis* (Green Tea)

Epigallocatechin-3-gallate (EGCG) reduces inflammatory cytokine production and cartilage degradation.[61] Experimental studies show inhibition of IL-1β-induced MMP expression.[62]

7.4 *Harpagophytum procumbens* (Devil's Claw)

Traditionally used in African medicine for musculoskeletal pain. Harpagoside reduces COX-2 expression and improves osteoarthritis symptoms.[63] Clinical trials demonstrate modest efficacy in knee OA.[64]

7.5 *Cissus quadrangularis*

Traditionally used for bone and joint disorders. Demonstrates anti-inflammatory and antioxidant properties in experimental arthritis.[65]

Table 2: Phytochemical Classes and Molecular Targets.

Phytochemical Class	Representative Compound	Molecular Target	References
Flavonoids	Quercetin	NF-κB, TNF-α	47-49
Polyphenols	Resveratrol	MAPK, ROS	50-51
Terpenoids	Boswellic acid	5-LOX	52
Alkaloids	Berberine	IL-17, Th17	54
Catechins	EGCG	MMPs	61-61

8. MECHANISMS OF ACTION

Plant-derived compounds exert multi-target actions

Inhibition of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), Suppression of NF-κB and JAK/STAT pathways, Reduction of oxidative stress and ROS, Inhibition of MMP-mediated cartilage degradation, Modulation of immune cell differentiation (Th1/Th17 suppression)[66-70]

9. CLINICAL EVIDENCE

Several randomized controlled trials have evaluated plant-based therapies:

Curcumin demonstrated comparable efficacy to diclofenac with improved safety.[71]

Boswellia serrata extract reduced pain and improved physical function in OA.[72]

Tripterygium wilfordii showed significant improvement in RA disease activity.[73]

Ginger extract reduced knee OA pain scores.[74]

Andrographis paniculata showed symptomatic benefit in RA.[75]

Table 3: Selected Clinical Trials of Anti-arthritic Medicinal Plants.

Plant	Study Design	Sample Size	Outcome	References
Curcuma longa	RCT	45	↓DAS28 score	71
Boswellia serrata	RCT	75	↓Knee pain	72
Tripterygium wilfordii	RCT	207	↓RA activity	73
Zingiber officinale	RCT	261	↓OA pain	74
Andrographis paniculata	RCT	60	Symptom relief	75

10. SAFETY, TOXICITY AND HERB–DRUG INTERACTIONS

While herbal medicines are often perceived as safe, adverse events have been documented:
Hepatotoxicity associated with *Tripterygium wilfordii*.[76]
Herb-induced liver injury from Tinospora cordifolia.[45]
Gastrointestinal irritation with high-dose ginger.[77]
Herb–drug interactions with anticoagulants and immunosuppressants require caution.[78]

11. CHALLENGES AND FUTURE PERSPECTIVES

Lack of standardization of herbal extracts.[79]
Variability in phytochemical composition.[80]
Limited large-scale clinical trials.[81]
Need for pharmacokinetic and toxicity profiling.[82]
Integration of omics-based validation approaches.[83]

Future research should emphasize bioactive compound isolation, mechanism-based drug design, and well-designed multicenter trials.[84,85]

12. CONCLUSION

Traditional anti-arthritic medicinal plants represent a valuable reservoir of bioactive compounds targeting inflammatory and degenerative pathways in arthritis. Integration of ethnopharmacology, phytochemistry, and modern validation provides a rational framework for novel therapeutic development. While promising, further rigorous clinical evaluation and safety standardization are required to translate traditional remedies into evidence-based therapeutics.

13. REFERENCES

1. Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity, 2017; 46: 183-96.
2. Smolen JS, Aletaha D. Rheumatoid arthritis therapy. Lancet, 2016; 388: 2023-38.
3. Hunter DJ, Bierma-Zeinstra SMA. Osteoarthritis. Lancet, 2019; 393: 1745-59.
4. Lanas A, Chan FKL. NSAID-induced gastrointestinal toxicity. N Engl J Med, 2017; 377: 2519-29.
5. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs. Lancet, 2013; 382: 769-79.
6. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol, 2016; 68: 1-26.
7. Newman DJ, Cragg GM. Natural products as sources of new drugs. J Nat Prod, 2016; 79: 629-61.
8. Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT, et al. Natural products in drug discovery: advances and opportunities. Biotechnol Adv, 2021; 48: 107772.
9. Pan SY, Litscher G, Gao SH, Zhou SF, Yu ZL, Chen HQ, et al. Historical perspective of traditional indigenous medical practices: the current renaissance and conservation of herbal resources. Chin Med, 2014; 9: 26.
10. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019. Lancet, 2020; 396: 1204-22.
11. Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Ann Rheum Dis, 2021; 80: 113-9.
12. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019. Lancet, 2020; 396: 1204-22.
13. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of hip and knee osteoarthritis. Ann Rheum Dis, 2014; 73: 1323-30.
14. World Health Organization. WHO Traditional Medicine Strategy 2014–2023. Geneva: WHO; 2013.
15. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis. Lancet, 2018; 391: 250-65.
16. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev, 2010; 233: 233-55.
17. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med, 2011; 365: 2205-19.
18. O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Nat Rev Rheumatol, 2013; 9: 313-28.
19. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Nat Rev Rheumatol, 2008; 4: 128-35.
20. Goldring MB, Goldring SR. Osteoarthritis. J Clin Invest, 2007; 117: 1217-27.
21. Lepetsos P, Papavassiliou AG. ROS/oxidative stress signaling in osteoarthritis. Biochim Biophys Acta, 2016; 1862: 576-91.
22. Robinson WH, Lepus CM, Wang Q, Raghu H, Mao R, Lindstrom TM, et al. Low-grade inflammation as a key mediator of osteoarthritis pathogenesis. Nat Rev Rheumatol, 2016; 12: 580-92.
23. Henrotin Y, Priem F, Mobasheri A. Curcumin: a new paradigm and therapeutic opportunity for the treatment of osteoarthritis. Nutrients, 2014; 6: 373-94.
24. Rahman MM, Ahmad SH, Mohamed MTM, Rahman MZ, Khalid KA. Ethnobotanical survey of medicinal plants used for treatment of inflammatory diseases. J Ethnopharmacol, 2015; 176: 238-53.
25. Aziz MA, Adnan M, Khan AH, Rehman AU, Jan R, Khan J, et al. Traditional uses of medicinal plants for inflammatory diseases. J Ethnobiol Ethnomed, 2018; 14: 35.
26. Sharma PV. Dravyaguna Vijnana. Varanasi: Chaukhambha Bharati Academy; 2001.

27. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China. Beijing: China Medical Science Press; 2015.
28. Van Wyk BE, Van Oudtshoorn B, Gericke N. Medicinal Plants of South Africa. Pretoria: Briza Publications; 2013.
29. Moerman DE. Native American Ethnobotany. Portland: Timber Press; 1998.
30. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect, 2001; 109: 69-75.
31. Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazón J. Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Phytochemistry, 2009; 70: 1233-44.
32. Dar PA, Mir MA, Kamal MA, Dar MA, Amin S, Ahmad S, et al. Withanolides from Withania somnifera: chemistry and pharmacological review. Phytochem Rev, 2015; 14: 653-67.
33. Gupta A, Mahdi AA, Shukla KK, Ahmad MK, Bansal N, Sankhwar SN, et al. Efficacy of Withania somnifera in inflammatory conditions. J Ethnopharmacol, 2014; 153: 507-14.
34. Chopra A, Saluja M, Tillu G, Venugopalan A, Narsimulu G, Handa R, et al. A randomized controlled trial of Withania somnifera in rheumatoid arthritis. Indian J Med Res, 2012; 136: 286-96.
35. Semwal RB, Semwal DK, Combrinck S, Viljoen A. Gingerols and shogaols: important nutraceutical principles from ginger. Phytochemistry, 2015; 117: 554-68.
36. Grzanna R, Lindmark L, Frondoza CG. Ginger—an herbal medicinal product with broad anti-inflammatory actions. J Med Food, 2005; 8: 125-32.
37. Altman RD, Marcussen KC. Effects of ginger extract on knee pain in patients with osteoarthritis. Arthritis Rheum, 2001; 44: 2531-8.
38. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods, 2017; 6: 92.
39. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin in inflammatory diseases. Int J Biochem Cell Biol, 2009; 41: 40-59.
40. Chandran B, Goel A. A randomized pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res, 2012; 26: 1719-25.
41. Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med, 2006; 72: 1100-16.
42. Sengupta K, Alluri KV, Satish AR, Mishra S, Golakoti T, Sarma KV, et al. A double blind, randomized, placebo controlled study of Boswellia extract in osteoarthritis of the knee. Arthritis Res Ther, 2008; 10: R85.
43. Saha S, Ghosh S. Tinospora cordifolia: one plant, many roles. Indian J Pharmacol, 2012; 44: 279-85.
44. Kapil A, Sharma S. Immunomodulatory activity of Tinospora cordifolia. J Ethnopharmacol, 1997; 58: 89-95.
45. Nagral A, Adhyaru K, Rudra OS, Gharat A, Sawant P, Mehta P, et al. Tinospora cordifolia-induced liver injury. J Clin Exp Hepatol, 2021; 11: 258-62.
46. Wink M. Modes of action of herbal medicines and plant secondary metabolites. Phytomedicine, 2015; 22: 657-66.
47. Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. J Nutr Sci, 2016; 5: e47.
48. Kim HP, Son KH, Chang HW, Kang SS. Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci, 2004; 96: 229-45.
49. Comalada M, Ballester I, Bailón E, Sierra S, Xaus J, Gálvez J, et al. Inhibition of pro-inflammatory markers in primary bone marrow-derived mouse macrophages by naturally occurring flavonoids. Eur J Immunol, 2005; 35: 584-92.
50. Scalbert A, Johnson IT, Saltmarsh M. Polyphenols: antioxidants and beyond. Am J Clin Nutr, 2005; 81: 215S-17S.
51. Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B. Effects of resveratrol in inflammatory arthritis. Inflammation, 2007; 30: 1-6.
52. Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HP. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther, 1992; 261: 1143-46.
53. Ikeda Y, Murakami A, Ohigashi H. Ursolic acid: an anti- and pro-inflammatory triterpenoid. Planta Med, 2008; 74: 158-63.
54. Wang X, He X, Zhang CF, Guo CR, Wang CZ, Yuan CS. Anti-arthritic effect of berberine on adjuvant-induced rheumatoid arthritis in rats. Biomed Pharmacother, 2017; 89: 887-93.
55. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol, 1999; 58: 1685-93.
56. Akbar S. Andrographis paniculata: a review of pharmacological activities and clinical effects. Altern Med Rev, 2011; 16: 66-77.
57. Burgos RA, Alarcón P, Quiroga J, Manosalva C, Hancke JL. Andrographis paniculata in rheumatoid arthritis: a randomized controlled trial. Phytomedicine, 2009; 16: 188-94.
58. Brinker AM, Ma J, Lipsky PE, Raskin I. Medicinal chemistry and toxicity of Tripterygium wilfordii. Phytomedicine, 2007; 14: 380-85.
59. Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in rheumatoid arthritis. Ann Intern Med, 2009; 151: 229-40.
60. Lv QW, Zhang W, Shi Q, Zheng WJ, Li X, Chen H, et al. Comparison of Tripterygium wilfordii Hook F with methotrexate in rheumatoid arthritis. Arthritis Rheumatol, 2015; 67: 182-91.

61. Singh R, Ahmed S, Islam N, Goldberg VM, Haqqi TM. Epigallocatechin-3-gallate inhibits interleukin-1β–induced expression of matrix metalloproteinases in human chondrocytes. Arthritis Res Ther, 2010; 12: R1.
62. Ahmed S, Rahman A, Hasnain A, Goldberg VM, Haqqi TM. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1β–induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Arthritis Rheum, 2002; 46: 2079-86.
63. Chrubasik S, Künzel O, Black A, Conradt C. A systematic review of Devil's claw (Harpagophytum procumbens) in osteoarthritis. Phytomedicine, 2007; 14: 371-80.
64. Chantre P, Cappelaere A, Leblan D, Guedon D, Vandermander J, Fournie B. Efficacy and tolerability of Harpagophytum extract in osteoarthritis. Phytomedicine, 2000; 7: 177-83.
65. Potu BK, Bhat KM, Rao MS, Nampurath GK, Chamallamudi MR, Nayak SR, et al. Anti-arthritic effects of Cissus quadrangularis extract. Clin Nutr, 2009; 28: 486-92.
66. Feldmann M, Brennan FM, Maini RN. Role of tumor necrosis factor alpha in rheumatoid arthritis. Annu Rev Immunol, 1996; 14: 397-440.
67. O'Shea JJ, Gadina M, Siegel RM. Cytokines and cytokine receptors in immunity and inflammation. Nat Rev Immunol, 2015; 15: 525-38.
68. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal, 2014; 20: 1126-67.
69. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci, 2006; 11: 529-43.
70. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells in autoimmunity. Annu Rev Immunol, 2009; 27: 485-517.
71. Chandran B, Goel A. A randomized pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res, 2012; 26: 1719-25.
72. Sengupta K, Alluri KV, Satish AR, Mishra S, Golakoti T, Sarma KV, et al. A double blind, randomized, placebo controlled study of Boswellia extract in osteoarthritis. Arthritis Res Ther, 2008; 10: R85.
73. Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in rheumatoid arthritis. Ann Intern Med, 2009; 151: 229-40.
74. Altman RD, Marcussen KC. Effects of ginger extract on knee pain in patients with osteoarthritis. Arthritis Rheum, 2001; 44: 2531-8.
75. Burgos RA, Alarcón P, Quiroga J, Manosalva C, Hancke JL. Andrographis paniculata in rheumatoid arthritis: a randomized controlled trial. Phytomedicine, 2009; 16: 188-94.
76. Xue M, Zhou ZW, Wu CF, Chen G, Yuan H, Li YH, et al. Tripterygium wilfordii Hook F–induced hepatotoxicity: mechanisms and prevention. Front Pharmacol, 2011; 2: 1-8.
77. Lete I, Allué J. The safety of ginger use in pregnancy: a systematic review and meta-analysis. Food Chem Toxicol, 2016; 97: 79-87.
78. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs, 2009; 69: 1777-98.
79. Heinrich M, Appendino G, Efferth T, Fürst R, Izzo AA, Kayser O, et al. Best practice in research – overcoming common challenges in phytopharmacological research. J Ethnopharmacol, 2018; 223: 136-48.
80. Li S, Zhang B, Jiang D, Wei Y, Zhang N. Herbal standardization and quality control: advances and challenges. Nat Prod Rep, 2019; 36: 142-68.
81. Venkatesha SH, Astry B, Nanjundaiah SM, Yu H, Moudgil KD. Suppression of autoimmune arthritis by herbal therapies: current gaps and future directions. Phytother Res, 2016; 30: 1-8.
82. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol, 2014; 4: 177.
83. Li J, Zhao P, Li Y, Tian Y, Wang Y, Zhao Y, et al. Omics approaches in herbal medicine research. Trends Pharmacol Sci, 2020; 41: 913-28.
84. Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT, et al. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov, 2021; 20: 200-16.
85. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades. J Nat Prod, 2020; 83: 770-803.